Robert E MacLaren
Overview
Explore the profile of Robert E MacLaren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
332
Citations
6241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
McClements M, Abdalla Elsayed M, Major L, de la Camara C, MacLaren R
Mol Diagn Ther
. 2024 Jul;
28(5):575-591.
PMID: 38955952
Gene therapies have emerged as promising treatments in clinical development for various retinal disorders, offering hope to patients with inherited degenerative eye conditions. Several gene therapies have already shown remarkable...
22.
Gocuk S, Edwards T, Jolly J, McGuinness M, MacLaren R, Chen F, et al.
Ophthalmol Retina
. 2024 Jun;
8(12):1200-1210.
PMID: 38936773
Purpose: To describe visual function and retinal features of female carriers of choroideremia (CHM), using multimodal imaging and microperimetry. Design: Cross-sectional cohort study. Participants And Controls: Choroideremia carriers seen in...
23.
Thirunavukarasu A, Hu M, Foster W, Xue K, Cehajic-Kapetanovic J, MacLaren R
Transl Vis Sci Technol
. 2024 Jun;
13(6):20.
PMID: 38916880
Purpose: Surgical innovation in ophthalmology is impeded by the physiological limits of human motion, and robotic assistance may facilitate an expansion of the surgical repertoire. We conducted a systematic review...
24.
Shamsnajafabadi H, Kaukonen M, Bellingrath J, MacLaren R, Cehajic-Kapetanovic J
Genes (Basel)
. 2024 May;
15(5).
PMID: 38790254
Pathogenic variants in the gene lead to severe, childhood-onset retinal degeneration leading to blindness in early adulthood. There are no approved therapies, and traditional adeno-associated viral vector-based gene therapy approaches...
25.
Yusuf I, Burgoyne T, Salman A, McClements M, MacLaren R, Charbel Issa P
Mol Ther
. 2024 Mar;
32(5):1445-1460.
PMID: 38504520
Age-related macular degeneration (AMD) is the most common cause of untreatable blindness in the developed world. Recently, CDHR1 has been identified as the cause of a subset of AMD that...
26.
Lam B, Pennesi M, Kay C, Panda S, Gow J, Zhao G, et al.
Ophthalmology
. 2024 Feb;
131(9):1083-1093.
PMID: 38423215
Purpose: Cotoretigene toliparvovec (BIIB112/AAV8-RPGR) is an investigational vector-based gene therapy designed to provide a full-length, codon-optimized retinitis pigmentosa GTPase regulator (RPGR) protein to individuals with RPGR-associated X-linked retinitis pigmentosa (XLRP)....
27.
Salman A, McClements M, MacLaren R
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38338978
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among the elderly in the developed world. Whilst AMD is a multifactorial disease, the involvement of the complement...
28.
MacLaren R, Lam B, Fischer M, Holz F, Pennesi M, Birch D, et al.
Am J Ophthalmol
. 2024 Feb;
263:35-49.
PMID: 38311152
Purpose: The NIGHT study aimed to assess the natural history of choroideremia (CHM), an X-linked inherited chorioretinal degenerative disease leading to blindness, and determine which outcomes would be the most...
29.
Waldock W, Taylor L, Sperring S, Staurenghi F, de la Camara C, Whitfield J, et al.
Ophthalmic Genet
. 2024 Jan;
45(2):210-217.
PMID: 38273808
Introduction: Molecular confirmation of pathogenic sequence variants in the CHM gene is required prior to enrolment in retinal gene therapy clinical trials for choroideremia. Individuals with mild choroideremia have been...
30.
Bellingrath J, Birtel J, Yusuf I, MacLaren R, Charbel Issa P
JAMA Ophthalmol
. 2023 Dec;
142(2):158-161.
PMID: 38153728
No abstract available.